2011年美国临床肿瘤学会年会对胰腺癌诊疗共识  

Consensus statements on the diagnosis and treatment of pancreatic carcinoma from 2011 American Society of Clinical Oncology Annual meeting

作　　者：张萦斐[1] 王捷[1] 

机构地区：[1]中山大学孙逸仙纪念医院普外科,广东广州510120

出　　处：《岭南现代临床外科》2012年第1期1-4,共4页Lingnan Modern Clinics in Surgery

基　　金：广东省自然科学基金(10151008901000138)

摘　　要：胰腺癌恶性程度高,早期缺乏明显症状与体征,目前又无简便可靠的诊断方法,早期诊断胰腺癌十分困难。在2011年ASCO会议上,学者针对一些与胰腺癌相关遗传性综合症和明显家族性胰腺癌的研究可能对胰腺癌患者早期的筛查和诊断提供了新的方向。对于大部分确诊胰腺癌时已丧失手术根治机会的患者,以吉西他滨为主的各种联合化疗是目前被医疗界唯一推荐的一线方案;此外对一些新颖的药物的研究如细胞毒素类药物S-1,针对EGFR,IGFR通路的潘尼单抗和MK0646和ganitumab以及hedgehog通路的抑制剂IPI-926的应用提高胰腺癌患者生活质量和延长生存时间。Pancreatic cancer is a lethal malignancy which is lack of warning signs or early symptoms, and till now there is no an early and efficacious diagnostic method. At the 2011 American Society of Clinical Oncology （ASCO） annual meeting, the studies of genetic syndromes and a significant family history for pancreatic cancer provide important information about the yield of screening and detection of early pancreatic cancer. The majority of patients present at a late stage have no chance to undergo classically radical operation at the time of diagnosis. Gemcitabine monotherapy, or its combination with other drugs, was the only accepted treatment worldwide due to the poor relative survival rate and the intractable symptom. Besides,the research of novel agents such as S-l, MK0646,Ganitumab and IPI-926 combining gemcitabine show a trend towards improved overall survival and quality of life.

关 键 词：胰腺癌 遗传 联合化疗 生存时间 

分 类 号：R735.9[医药卫生—肿瘤]